Pricing

Paradigm Biopharma

0 followers

‌

Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.

Industries

Headquarters

Melbourne, Australia

Employees

Links

Org chart

Founder & Chairman

Collapse

Director of Investor Relations

Michelle Coffey

Global Head of Regulatory Affairs

Chief Medical Officer and Executive Director

Clinical Operations Lead

Director Of Business Operations

Board & advisors

Non-Executive Director

Non-Executive Director

Kevin Hollingsworth

Company Secretary

Teams

Leadership Team

3 people · 0 jobs

Clinical Operations Team

3 people · 0 jobs

Regulatory and Scientific Affairs Team

3 people · 0 jobs

Finance and Investor Relations Team

2 people · 0 jobs

Offices

HQ
3 positions, 0 job posts
SH

Similar companies

Arthritis Knee Pain Centers

2 followers

Harrison.ai

3 followers

AstraZeneca

407 followers

Bayer

312 followers

Bristol-Myers Squibb

250 followers

UCB

45 followers

Astellas Pharma

40 followers

NYU Langone Health

23 followers

Tilray

19 followers

Perrigo

16 followers

West Pharmaceutical Services

8 followers

Explore companies